

**August 22, 2025**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation under Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Environmental, Social and Governance (ESG) Rating**

---

Pursuant to Regulations 30 & 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that the Crisil ESG Ratings & Analytics Limited, a SEBI registered ESG Rating Provider has voluntarily assigned an ESG rating of “Crisil ESG 57” to the Company, based on publicly disclosed information for the fiscal year 2025.

As per the category defined by CRISIL, rating between 51-60 is considered as “adequate”.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
**Company Secretary and Compliance Officer**